Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Declines By 68.7%

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 21,800 shares, a drop of 68.7% from the June 30th total of 69,600 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 37,100 shares, the short-interest ratio is currently 0.6 days.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research report on Friday, June 28th. Oppenheimer upped their price target on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, July 10th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of CalciMedica in a research report on Tuesday, July 9th.

Insider Buying and Selling

In other news, Director Robert N. Wilson acquired 8,443 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average price of $3.23 per share, for a total transaction of $27,270.89. Following the acquisition, the director now owns 258,918 shares of the company’s stock, valued at $836,305.14. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 53.30% of the stock is currently owned by corporate insiders.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Meritage Portfolio Management raised its position in CalciMedica, Inc. (NASDAQ:CALC) by 360.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 46,000 shares of the company’s stock after buying an additional 36,000 shares during the quarter. Meritage Portfolio Management owned about 0.81% of CalciMedica worth $132,000 as of its most recent filing with the SEC.

CalciMedica Stock Performance

NASDAQ:CALC opened at $3.88 on Friday. CalciMedica has a 52-week low of $1.75 and a 52-week high of $8.38. The stock’s 50 day moving average price is $4.85 and its 200 day moving average price is $4.76.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. As a group, equities research analysts predict that CalciMedica will post -2.08 EPS for the current year.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.